TriSalus this week said it appointed Rajesh Mistry as chief financial officer.
Mistry brings more than 15 years of experience to the company. He most recently served as head of corporate development at Option Care Health. He has also held numerous leadership positions at Melinta Therapeutics, Baxter International and A.G. Edwards Capital Markets.
“We are very pleased to have Raj lead our finance team as we work to execute our cell therapy and immunomodulation asset acquisition strategy and transition the company to deliver a combination of cutting-edge therapies to attack solid tumors,”
president and CEO Mary Szela said in a news release. “Additionally, his proven strategic, industry and Wall Street expertise further strengthens our leadership team and positions the company for future success and continued growth.”
“I am very excited to join Mary and the TriSalus team in their commitment to transforming the lives of patients suffering from solid tumors. I am looking forward to putting my financial and strategic expertise to use as TriSalus moves forward with its bold treatment strategy,” said Mistry.
